Super Vilitra is a combination medicine used to treat erectile dysfunction (ED) and premature ejaculation (PE). It contains vardenafil (a PDE5 inhibitor that improves blood flow) and dapoxetine (a short-acting SSRI that delays ejaculation).

For men with vascular diseases (such as coronary artery disease, peripheral artery disease, or hypertension-related vessel damage), suitability must be assessed very carefully. The vardenafil component works by dilating blood vessels and increasing blood flow to the penis, which can also affect blood pressure and cardiovascular workload.

In many cases, PDE5 inhibitors like vardenafil may be used in stable cardiovascular patients, but only under strict medical supervision. Men with unstable angina, recent heart attack, uncontrolled hypertension, or severe heart failure are generally advised to avoid sexual activity and medications like Super Vilitra until cleared by a cardiologist.

The dapoxetine component can also cause side effects such as dizziness or blood pressure changes, which may be more pronounced in individuals with compromised vascular health.

A major safety concern is interaction with nitrates (used for chest pain). Combining nitrates with vardenafil can cause a dangerous drop in blood pressure, which can be life-threatening.

Overall, Super Vilitra is not absolutely contraindicated in all vascular disease patients, but it is only suitable for carefully selected, stable patients under medical supervision. A doctor should evaluate heart function, blood pressure control, and medication history before use to ensure safety.